VILLEURBANNE, Francia–(BUSINESS WIRE)–Bollé Safety quiere contribuir a proteger el planeta. En 2021, la marca mundial de protección ocular se ha puesto manos a la obra con su plan Go Green. Sostenibilidad: un proceso a largo plazo Los productos de Bo…
Author: Business Wire
Bollé Safety, le spécialiste des lunettes de protection, lance Go Green : un plan d'action concret pour protéger l'environnement
VILLEURBANNE, France–(BUSINESS WIRE)–Bollé Safety veut apporter sa pierre à l’édifice pour protéger la planète. En 2021, la marque mondiale de protection oculaire passe à la vitesse supérieure avec son plan Go Green. Le développement durable : une dé…
Resumen: iHealthScreen Inc. anuncia la certificación CE por iPredict™, un sistema de IA automatizado para el diagnóstico temprano de retinopatía diabética, degeneración macular senil y posible glaucoma
NUEVA YORK–(BUSINESS WIRE)–iPredict™, un sistema de IA para la revisión ocular ofrece exámenes diagnósticos de retinopatía diabética, degeneración macular senil y posible glaucoma completamente automatizados, que incluyen la tomografía retinal y la n…
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it plans…
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that OptumRx, one of …
iHealthScreen Inc. annuncia di avere ottenuto la certificazione CE per il sistema di IA automatizzato iPredict™ progettato per la diagnosi precoce della retinopatia diabetica (DR), della degenerazione maculare legata all’età (DMLE)…
NEW YORK–(BUSINESS WIRE)– iHealthScreen Inc. annuncia di avere ottenuto la certificazione CE per il sistema di IA automatizzato iPredict™ progettato per la diagnosi precoce della retinopatia diabetica (DR), della degenerazione maculare legata all’et…
iHealthScreen Inc. meldet CE-Zertifizierung für automatisiertes KI-System iPredict™ zur Früherkennung von diabetischer Retinopathie (DR) und altersbedingter Makuladegeneration (AMD) sowie bei Verdacht auf Glaukom
NEW YORK–(BUSINESS WIRE)–Das iPredict™ AI Eye Screening System bietet vollständig automatisierte Früherkennung von diabetischer Retinopathie (DR) und altersbedingter Makuladegeneration (AMD) sowie bei Glaukom-Verdachtsfällen, einschließlich Netzhautb…
iHealthScreen Inc. annonce la certification CE du système IA automatisé iPredict™ pour le dépistage précoce de la rétinopathie (RD), la dégénérescence maculaire liée à l'âge (DMLA) et les cas suspects de glaucome
NEW YORK–(BUSINESS WIRE)–iPredict™ un système d’intelligence artificielle (IA) d’analyse de l’œil permet le dépistage entièrement automatique de la rétinopathie (RD), la dégénérescence maculaire liée à l’âge (DMLA) et les cas suspects de glaucome, y …
Samenvatting: iHealthScreen Inc. kondigt CE-certificering aan voor iPredict™ geautomatiseerd AI-systeem voor vroege diagnose van diabetische retinopathie (DR), Age Related Macular Degeneration (AMD) en glaucoom-verdachte
NEW YORK–(BUSINESS WIRE)–iPredict™ AI Eye Screening System biedt volledig geautomatiseerde diabetische retinopathie (DR), age related macular degeneration (AMD), en glaucoom verdachte screening, inclusief retinale beeldvorming en onmiddellijke rappor…
iHealthScreen Inc. Announces CE Certification for iPredict™ Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD), and Glaucoma Suspect
NEW YORK–(BUSINESS WIRE)– #AI–iHealthScreen’s AI-based software tool received CE Certification of diabetic retinopathy (DR), macular degeneration, and glaucoma suspect screening.
EnChroma Names Former Marvel and Remington CEO, and Previous SBIR Chief Technologist and Eisenhower Fellow, to Board of Directors
BERKELEY, Calif.–(BUSINESS WIRE)– #colorishere–Peter Cuneo, Former Marvel and Remington CEO, and SBIR Chief Technologist G. Nagesh Rao, Join EnChroma Board to Guide Leader in Color Blind Glasses
Avellino Launches AvaGen Nationwide as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophies
MENLO PARK, Calif.–(BUSINESS WIRE)– #astigmatism–Avellino launches AvaGen nationwide as the first genetic test to quantify keratoconus risk and presence of corneal dystrophies for early detection.
Benefits in a Pandemic: NaturalVue® Offers Multiple Solutions for Patients and Eye Care Practitioners
ATLANTA–(BUSINESS WIRE)–Visioneering Technologies is pleased to provide an update on the impact of NaturalVue on practice dynamics and patients’ lives.
Vision Care Market Forecast to 2027: Focus on Eye Glasses, Contact Lens, Intraocular Lens, Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product Type ( Eye Glasses, Contact Lens, Intraocular Lens, Others ); Distribution Channel ( Retail Stores, E-Commerce, Clinics, Hospitals )” r…
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restorat…
NOXXON GIBT POSITIVE ERGEBNISSE DER ZWEITEN KOHORTE IN PHASE-1/2-NOX-A12-GEHIRNTUMORSTUDIE BEKANNT
BERLIN, Deutschland–(BUSINESS WIRE)–NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch gezielte Einwirkung auf die Tumormikroumgebung (TME) konzentrie…
NOXXON ANNONCE LES RESULTATS POSITIFS DE LA SECONDE COHORTE DE SON ESSAI DE PHASE 1/2 ÉVALUANT LE NOX-A12 DANS LE CANCER DU CERVEAU
BERLIN, Allemagne–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris : ALNOX), société de biotechnologie spécialisée dans le développement de traitements améliorés du cancer ciblant le microenvironnement tumoral …
NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial
BERLIN, Germany–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today positive r…
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Insights on the Tonometers Global Market to 2027 – 40 Players Featured Accutome, Amtek and Oculus Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Tonometers – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Amid the COVID-19 crisis, the global market for Tonometers estimated at US$340.5 Million in the year 2020, …